KARDİYOVASKÜLER HASTALIĞI BULUNAN VE HASTANEYE YATIŞI YAPILAN HASTALARIN İLAÇ PROFİLLERİNİN DEĞERLENDİRİLMESİ

Öz

Çalışmamızda, kardiyovasküler hastalığa ek olarak farklı kronik hastalığı bulunan ve kardiyoloji servisine yatışı yapılan hastaların kullandıkları ilaçların değerlendirilmesi ve olası medikasyon hatalarının belirlenmesi amaçlanmıştır. Çalışmaya Türkiye’nin doğusundaki bir devlet hastanesinin kardiyoloji servisine yatışı yapılan hastalardan, en az iki gün yatışı yapılan ve ek kronik hastalığı bulunan 110 hasta dahil edilmiştir. Çalışmada kullanılan bilgiler hasta dosyalarından elde edilmiştir. Hastaların klinik yatışları sırasında aldıkları tanılar incelenmiştir. Buna göre akut koroner sendrom (%33.6) en fazla yatış nedeni olarak belirlenmiştir. Hastaların %90’ında hipertansiyon bulunmaktadır. Çalışmaya dahil edilen hastalara toplam 1061 ilaç reçete edilmiştir ve en fazla reçetelenen ilaç/ilaç grupları beta-blokörler, proton pompa inhibitörleri, antiplatelet ajanlardır. Bütün ilaçlar ilaç etkileşimleri bakımından incelenmiştir ve toplam 1024 ilaç etkileşimi tespit edilmiştir. Etkileşimlerde en sık yer alan ilaçlar ise asetilsalisik asit ve beta-blokörlerdir. STOPP/START kriterlerinde değerlendirilen 42 hastada toplam 89 kriter uyumsuzluğu tespit edilmiştir. Ayrıca ilaçlar ilaç uygunluk indeksine göre incelenmiş ve ilaçların aldıkları puan ortalaması 9.89 olarak belirlenmiştir. Kardiyovasküler hastalıklar toplumda sık rastlanan hastalıklardır ve genellikle çoklu ilaç kullanımı gerektirdiğinden ilaç etkileşimlerine daha sık rastlanmaktadır. Çoklu ilaç kullanan hastalarda kullanılan ilaçlar arasındaki etkileşme riski değerlendirilmeli ve hastaların olası yan etkiler nedeniyle takipleri planlanmalıdır.

Anahtar Kelimeler

• İlaç etkileşimleri
• Kardiyovasküler anomaliler
• İlaç Kullanımını Değerlendirme

EVALUATION OF MEDICATION PROFILES OF HOSPITALIZED PATIENTS WITH CARDIOVASCULAR DISEASE

Öz

This study aims to evaluate the medication use of patients hospitalized in the cardiology ward with different chronic conditions in addition to cardiovascular disease and to identify potential medication errors. The study included 110 patients who were admitted to the cardiology service of a public hospital in eastern Turkey, who were hospitalized for at least two days and who had additional chronic diseases. Information from the patients' medical records was analyzed and the diagnoses received during hospitalization were evaluated. Acute coronary syndrome (33.6%) was the most common reason for hospitalization, while 90% of the patients had hypertension. A total of 1061 drugs were prescribed to the patients participating in the study, with the most commonly prescribed drugs and drug groups being beta-blockers, proton pump inhibitors and antiplatelet agents. All drugs were evaluated for drug interactions and 1024 drug interactions were identified. The most common drugs found in interactions were acetylsalicylic acid and beta-blockers. A total of 89 criteria non-compliances were found in 42 patients evaluated under STOPP/START criteria. As a result of the medication appropriateness index analysis, the mean score of the medications was 9.89. Cardiovascular diseases are common diseases in the community and usually require the use of multiple drugs, so drug interactions are more common. It is important to evaluate the risk of drug interactions in patients using multiple drugs and to plan regular follow-up of patients due to possible side effects.

Anahtar Kelimeler

• Drug interactions
• Drug Utilization Evaluation
• Cardiovascular anomalies.

Kaynakça

1. Algabbani, A. M., & Alangari, A. S. (2023). Proton pump inhibitor prescribing patterns and utilization: A retrospective chart review analysis. Saudi Pharmaceutical Journal, 31(12), 101841. https://doi.org/10.1016/j.jsps.2023.101841
2. Arıkan, İ., Metintaş, S., Kalyoncu, C., & Yıldız, Z. (2009). Kardiyovasküler hastalıklar risk faktörleri bilgi düzeyi (KARRİF-BD) ölçeği’nin geçerlik ve güvenirliği. Türk Kardiyol Dern Arş, 37(1), 35-40.
3. Arslan, Ş., Atalay, A., Gökçe Kutsal, Y. . (2000). Yaşlılarda ilaç tüketimi. Geriatri, 3 (2), 56-60.
4. Fonseca, V. A. (2010). Effects of β-blockers on glucose and lipid metabolism. Current medical research and opinion, 26(3), 615-629. https://doi.org/10.1185/03007990903533681
5. Frankenthal, D., Lerman, Y., Kalendaryev, E., & Lerman, Y. (2013). Potentially inappropriate prescribing among older residents in a geriatric hospital in Israel. International journal of clinical pharmacy, 35(5), https://doi.org/10.1007/s11096-013-9790-z of 677-682.
6. Gallagher, P., & O’Mahony, D. (2008). STOPP (Screening Tool Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age and ageing, 37(6), 673 679. https://doi.org/10.1093/ageing/afn197
7. Gillespie, U., Alassaad, A., Hammarlund-Udenaes, M., Mörlin, C., Henrohn, D., Bertilsson, M., & Melhus, H. (2013). Effects of pharmacists' interventions on appropriateness of prescribing and evaluation of the instruments'(MAI, STOPP and STARTs') ability to predict hospitalization–analyses from a randomized controlled trial. Plos one, 8(5), e62401. https://doi.org/10.1371/journal.pone.0062401
8. Hanlon, J. T., & Schmader, K. E. (2013). The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs & aging, 30(11), 893 900. https://doi.org/10.1007/s40266-013-0118-4

9. Jain, S., Jain, P., Sharma, K., & Saraswat, P. (2017). A prospective analysis of drug interactions in patients of intensive cardiac care unit. Journal of clinical and diagnostic research: JCDR, 11(3), https://doi.org/10.7860/jcdr/2017/23638.9403 FC01.
10. Kara, Ö., Arık, G., Kızılarslanoglu, M. C., Kılıc, M. K., Varan, H. D., Sümer, F., Esme, M., Altıner, S., Kuyumcu, M. E., & Yesil, Y. (2016). Potentially inappropriate prescribing according to the STOPP/START criteria for older adults. Aging clinical and experimental research, 28(4), 761-768. https://doi.org/10.1007/s40520-015-0475-4
11. Kelleci Çakır, B. (2017). Geriatri Polikliniği ve Huzurevi Hastalarının STOPP/START ve MAI Kriterleri ile Değerlendirilmesi ve Müdahalelerin Yapılmasında Klinik Eczacının Rolü. Institute of Health Sciences, Yayınlanmamış Doktora Tezi. Hacettepe University, Ankara.
12. Masoodi, N. A. (2008). To Err is Human, To Correct Divine. British Journal of Clinical Pharmacology, 1 (1), 6–9. Mateti, U., Rajakannan, T., Nekkanti, H., Rajesh, V.,
13. Mallaysamy, S., & Ramachandran, P. (2011). Drug-drug interactions in hospitalized cardiac patients. Journal of Young Pharmacists, 3(4), 329-333. https://doi.org/10.4103/0975 1483.90246
14. Moura, C. S., Acurcio, F. A., & Belo, N. O. (2009). Drug drug interactions associated with length of stay and cost of hospitalization. Journal of Pharmacy & Pharmaceutical Sciences, 12(3), 266-272. https://doi.org/10.18433/j35c7z
15. O'Mahony, D., O'sullivan, D., Byrne, S., O'Connor, M. N., Ryan, C., & Gallagher, P. (2014). STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age and ageing, https://doi.org/10.1093/ageing/afu145 44(2), 213-218.
16. Özdemir, Ü., & Taşçı, S. (2013). Kronik hastaliklarda psikososyal sorunlar ve bakim. ERÜ Sağlık Bilimleri Fakültesi Dergisi, 1(1), 57-72.
17. Passarelli, M. C. G., Jacob-Filho, W., & Figueras, A. (2005). Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs & aging, 22(9), 767-777. 200522090-00005 https://doi.org/10.2165/00002512
18. Queneau, P., Bannwarth, B., Carpentier, F., Guliana, J.-M., Bouget, J., Trombert, B., Leverve, X., Lapostolle, F., Borron, S. W., & Adnet, F. (2007). Emergency department visits caused by adverse drug events: results of a French survey. Drug Safety, 30(1), 81-88. https://doi.org/10.2165/00002018 200730010-00008
19. Rodrigues, A. T., Stahlschmidt, R., Granja, S., Falcao, A. L. E., Moriel, P., & Mazzola, P. G. (2015). Clinical relevancy and risks of potential drug–drug interactions in intensive therapy. Saudi Pharmaceutical Journal, 23(4), 366-370. https://doi.org/10.1016/j.jsps.2014.11.014
20. Smithburger, P. L., Kane-Gill, S. L., & Seybert, A. L. (2012). Drug–drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved. International Journal of Pharmacy Practice, 20(6), 402-408. https://doi.org/10.1111/j.2042-7174.2012.00221.x
21. Tziomalos, K., Athyros, V. G., Karagiannis, A., & Mikhailidis, D. P. (2011). Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. The open cardiovascular medicine journal, 5, 85. https://doi.org/10.2174/1874192401105010085
22. Uijtendaal, E. V., van Harssel, L. L., Hugenholtz, G. W., Kuck, E. M., Zwart‐van Rijkom, J. E., Cremer, O. L., & Egberts, T. C. (2014). Analysis of potential drug‐drug interactions in medical intensive care unit patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 41 34(3), 213-219. https://doi.org/10.1002/phar.1395
23. Weir, M. R., & Moser, M. (2000). Diuretics and β-blockers: Is there a risk for dyslipidemia? American heart journal, 139(1), 174-184. 8703(00)90325-9
24. World Health https://doi.org/10.1016/s0002 Organization. (2020, December). Noncommunicable diseases. https://www.who.int/news room/fact-sheets/detail/noncommunicable-diseases
25. Yayla, M. E., Bilge, U., Binen, E., & Keskin, A. (2013). The use of START/STOPP criteria for elderly patients in primary care. The Scientific World Journal, 2013(1), 165873. https://doi.org/10.1155/2013/165873
26. Yerebakan, G., Yazicioglu, B., & Ozturk, O. (2025). Evaluation Of Proton Pump Inhibitor Use Of Patients Enrolled In Family Health Centers In Terms Of Rational Drug Use. International Journal of Current Medical and Biological Sciences, 5(2), https://doi.org/10.5281/zenodo.15988243 61-67.
27. Zwart‐van Rijkom, J. E., Uijtendaal, E. V., Ten Berg, M. J., Van Solinge, W. W., & Egberts, A. C. (2009). Frequency and nature of drug–drug interactions in a Dutch university hospital. British Journal of Clinical Pharmacology, 68(2), 187-193. https://doi.org/10.1111/j.1365-2125.2009.03443.x